AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Bullous Pemphigoid Epidemiology Forecast Report 2018-2020 & 2021-2030 - ResearchAndMarkets.com

April 15, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Apr 15, 2021--

The “Bullous Pemphigoid - Epidemiology Forecast 2030” report has been added to ResearchAndMarkets.com’s offering.

This ‘Bullous Pemphigoid-Epidemiology Forecast-2030’ report deliver an in-depth understanding of the Bullous Pemphigoid historical and forecasted epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

ADVERTISEMENT

Bullous Pemphigoid Overview

Bullous Pemphigoid (BP) is an acquired autoimmune subepidermal bullous disease in which autoantibodies are directed against the skin’s basement membrane zone components. Mainly IgG (rarely IgA, IgM, and IgE) autoantibodies bind to components of the hemidesmosome adhesion complex, the BP230, and BP180 antigens.

It is characterized by blistering, urticarial lesions (hives), and itching. Less commonly, these blisters can involve the mucous membranes, including the eyes, oral mucosa, esophagus, and genital mucosa. It typically presents in older adults as a generalized intensely itchy blistering skin condition.

Bullous Pemphigoid Diagnosis

The initial evaluation of a patient with bullous pemphigoid includes medical history, physical examination, and clinical symptoms, including affected area and number of blisters per day. Direct and Indirect Immunofluorescence microscopy tests and ELISA are some of the most common diagnostic techniques. Diagnostic delay is quite common as the usual delay is ~6 months.

Bullous Pemphigoid Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Bullous Pemphigoid, Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid, Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid, and Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Bullous Pemphigoid Detailed Epidemiology Segmentation

  • In 2020, the total diagnosed prevalent cases of bullous pemphigoid in the 7MM were 124,517 which is likely to increase by 2030 at a CAGR of 0.96% for the study period (2018-2030).
  • In 2020, there were 25,041 diagnosed prevalent cases of bullous pemphigoid in the United States, these cases are expected to increase at a CAGR of 1.26% for the study period of 2018-2030.
  • Assessments as per this analysis showed that there were 13,772 cases of the mild-moderate form of bullous pemphigoid and 11,268 cases of the severe form of bullous pemphigoid in the United States in 2020.
  • Assessments as per the analysts showed that 47% of total cases of bullous pemphigoid in the United States in 2020 were from the age group above 80 years.
  • In 2020, males and females contributed to 44% and 56% of the total diagnosed prevalent cases of Bullous Pemphigoid in the United States, respectively.
  • Among the European countries, the UK had the highest diagnosed prevalent population of bullous pemphigoid with 24,644 cases, followed by France which had 23,843 diagnosed prevalent cases in 2020. On the other hand, Spain had the lowest diagnosed prevalent population of 10,920 in 2020.
  • In 2020, Japan accounted for 8,619 diagnosed prevalent cases of bullous pemphigoid which is the least cases among 7MM countries.

ADVERTISEMENT

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Bullous Pemphigoid Epidemiology Overview at a Glance

3.1. Epidemiology Share (%) Distribution of Bullous Pemphigoid in 2018

3.2. Epidemiology Share (%) Distribution of Bullous Pemphigoid in 2030

4. Executive Summary of Bullous Pemphigoid

5. Disease Background and Overview

5.1. Introduction

5.2. Types of Bullous Pemphigoid

5.3. Causes

5.4. Symptoms of Bullous Pemphigoid

5.5. Pathogenesis of Bullous Pemphigoid

5.5.1. Neurologic disorders and BP

5.5.2. Malignancies in BP

5.5.3. Thrombotic risk and BP

5.6. Biomarkers of Bullous Pemphigoid

5.6.1. BP-related autoantibodies as biomarkers of BP disease

5.6.2. Inflammation and biomarkers in BP disease

5.6.2.1. Markers of BP activity and severity

5.6.2.2. Markers of BP outcome

5.7. Genetic Analysis

5.8. Diagnosis of Bullous Pemphigoid

5.8.1. History

5.8.2. Clinical manifestation

5.8.3. Histological examination

5.8.4. Direct Immunopathological tests

5.8.5. Indirect immunofluorescence tests

5.8.6. ELISA tests

5.8.7. Differential diagnosis

5.8.8. Diagnostic Algorithm of Bullous Pemphigoid

5.9. Diagnostic Guidelines of Bullous Pemphigoid

5.9.1. Japanese guidelines for the management of Pemphigoid (including epidermolysis bullosa acquisita [EBA])

5.9.1.1. Diagnostic criteria

5.9.1.2. Disease severity determination criteria

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Total Diagnosed Prevalent Cases of Bullous Pemphigoid in the 7MM

6.4. Epidemiology of Bullous Pemphigoid

6.5. The United States

6.5.1. Diagnosed Prevalent Cases of Bullous Pemphigoid in the US

6.5.2. Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the US

6.5.3. Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the US

6.5.4. Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid in the US

6.6. EU5

6.6.1. Germany

6.6.2. France

6.6.3. Italy

6.6.4. Spain

6.6.5. The United Kingdom

6.7. Japan

7. KOL Views

8. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ii1ezw

View source version on businesswire.com:https://www.businesswire.com/news/home/20210415005567/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 04/15/2021 07:58 AM/DISC: 04/15/2021 07:58 AM

http://www.businesswire.com/news/home/20210415005567/en